{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T17:21:03Z","timestamp":1787764863258,"version":"build-2784847793"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"Abstract<\/jats:title>\n \n Background:<\/jats:title>\n Polyethylene glycol loxenatide (peg-loxenatide) is a novel glucagon-like peptide-1 receptor agonist developed and available for clinical use in China. This meta-analysis was performed as no meta-analysis has analysed the efficacy and safety of peg-loxenatide in type 2 diabetes (T2DM).<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Electronic databases were systematically reviewed for RCTs having patients living with T2DM receiving peg-loxenatide in treatment arm and placebo\/any other diabetes medicine in control arm. The primary outcome was to evaluate changes in glycated haemoglobin. The secondary outcomes were to evaluate alterations in weight, blood pressure, fasting glucose, prandial glucose, lipids, and adverse events.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Data from four trials (718 patients) were analysed. Over 12\u201324 weeks of clinical use, HbA1c was significantly lower in patients receiving standard-dose peg-loxenatide (100 mcg\/week) {MD -0.95% [95% confidence interval (CI): -1.19 to -0.71];\n P<\/jats:italic>\n < 0.01; I\n 2<\/jats:sup>\n = 76%} and high-dose peg-loxenatide (200 mcg\/week) [MD -1.15% (95% CI: -1.47 to -0.82);\n P<\/jats:italic>\n < 0.01; I\n 2<\/jats:sup>\n = 90%], as compared to placebo. Standard-dose peg-loxenatide was not associated with increased occurrence of nausea [RR 2.87 (95% CI: 0.56 to 14.72);\n P<\/jats:italic>\n = 0.21; I\n 2<\/jats:sup>\n = 10%], vomiting [RR 4.73 (95% CI: 0.53 to 41.88);\n P<\/jats:italic>\n = 0.16; I\n 2<\/jats:sup>\n = 0%], and anorexia [RR 0.78 (95% CI: 0.18 to 3.28);\n P<\/jats:italic>\n = 0.73; I\n 2<\/jats:sup>\n = 0%]. Occurrence of nausea [RR 16.85 (95% CI: 3.89 to 72.92);\n P<\/jats:italic>\n < 0.01; I\n 2<\/jats:sup>\n = 10%], vomiting [RR 15.90 (95% CI: 2.99 to 84.55);\n P<\/jats:italic>\n < 0.01; I\n 2<\/jats:sup>\n = 0%], and anorexia [RR 3.85 (95% CI: 1.24 to 11.88);\n P<\/jats:italic>\n = 0.02; I\n 2<\/jats:sup>\n = 0%] was significantly higher with high-dose peg-loxenatide, as compared to placebo.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n Peg-loxenatide (100 mcg\/week) is the most appropriate dose for clinical use as it is associated with good glycaemic efficacy with minimal gastro-intestinal side effects.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijem.ijem_162_23","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T04:25:43Z","timestamp":1698639943000},"page":"377-386","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Role of Novel Glucagon-like Peptide-1 Receptor Analogue Polyethylene Glycol Loxenatide in Type 2 Diabetes: A Systematic Review and Meta-analysis"],"prefix":"10.4103","volume":"27","author":[{"given":"Deep","family":"Dutta","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Center for Endocrinology Diabetes Arthritis and Rheumatism (CEDAR) Super-speciality Healthcare, Dwarka, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhankar","family":"Chatterjee","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Medical College and Hospital, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyankar K.","family":"Datta","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ritin","family":"Mohindra","sequence":"additional","affiliation":[{"name":"Department of Medicine, Post-graduate Institute of Medical Education and Research, Chandigarh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meha","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Center for Endocrinology Diabetes Arthritis and Rheumatism (CEDAR) Super-speciality Healthcare, Dwarka, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"key":"R1-20240828","doi-asserted-by":"crossref","first-page":"513","DOI":"10.31128\/AJGP-07-21-6057","article-title":"Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes","volume":"51","author":"Ng","year":"2022","journal-title":"Aust J Gen Pract"},{"key":"R2-20240828","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/jcph.386","article-title":"Pharmacokinetics and pharmacodynamics of a polyethylene glycol (PEG)-conjugated GLP-receptor agonist once weekly in Chinese patients with type 2 diabetes","volume":"55","author":"Yang","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"R3-20240828","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1111\/bcp.14091","article-title":"Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: A pharmacokinetic study","volume":"85","author":"Wang","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"R4-20240828","doi-asserted-by":"crossref","first-page":"879294","DOI":"10.3389\/fmolb.2022.879294","article-title":"Polyethylene glycol loxenatide injection (GLP-1) protects vascular endothelial cell function in middle-aged and elderly patients with type 2 diabetes by regulating gut microbiota","volume":"9","author":"Chen","year":"2022","journal-title":"Front Mol Biosci"},{"key":"R5-20240828","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1111\/1753-0407.12397","article-title":"Polyethylene glycol loxenatide injections added to metformin effectively improve glycemic control and exhibit favorable safety in type 2 diabetic patients","volume":"9","author":"Chen","year":"2017","journal-title":"J Diabetes"},{"key":"R6-20240828","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1111\/dom.14163","article-title":"Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: A multicentre, randomized, double-blind, placebo-controlled, phase 3b trial","volume":"22","author":"Gao","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"R7-20240828","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"R8-20240828","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3803\/EnM.2020.818","article-title":"Efficacy and safety of the novel dipeptidyl peptidase-4 inhibitor gemigliptin in the management of type 2 diabetes: A meta-analysis","volume":"36","author":"Dutta","year":"2021","journal-title":"Endocrinol Metab (Seoul)"},{"key":"R9-20240828","doi-asserted-by":"crossref","first-page":"102697","DOI":"10.1016\/j.dsx.2022.102697","article-title":"Efficacy and safety of novel thiazolidinedione lobeglitazone for managing type-2 diabetes a meta-analysis","volume":"17","author":"Dutta","year":"2022","journal-title":"Diabetes Metab Syndr"},{"key":"R10-20240828","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate healthcare interventions: Explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"R11-20240828","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: An emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R12-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta4100","article-title":"Publication and related biases","volume":"4","author":"Song","year":"2000","journal-title":"Health Technol Assess"},{"key":"R13-20240828","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/dom.14198","article-title":"Efficacy and safety of polyethylene glycol loxenatide monotherapy in type 2 diabetes patients: A multicentre, randomized, double-blind, placebo-controlled phase 3a clinical trial","volume":"23","author":"Shuai","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"R14-20240828","first-page":"7996","article-title":"Effect of polyethylene Glycol Loxenatide (long-acting GLP-1RA) on lipid, glucose levels and weight in type 2 diabetes mellitus patients with obesity","volume":"26","author":"Li","year":"2022","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"R15-20240828","doi-asserted-by":"crossref","first-page":"1106868","DOI":"10.3389\/fendo.2023.1106868","article-title":"Short-term effect of polyethylene glycol loxenatide on weight loss in overweight or obese patients with type 2 diabetes: An open-label, parallel-arm, randomized, metformin-controlled trial","volume":"14","author":"Cai","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R16-20240828","doi-asserted-by":"crossref","first-page":"108656","DOI":"10.1016\/j.diabres.2021.108656","article-title":"Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis","volume":"172","author":"Li","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"R17-20240828","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s12020-018-1708-z","article-title":"The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: A systemic review and meta-analysis","volume":"62","author":"Li","year":"2018","journal-title":"Endocrine"},{"key":"R18-20240828","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s12020-020-02193-9","article-title":"Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes: A systematic review and meta-analysis of 21 randomized controlled trials","volume":"68","author":"Qie","year":"2020","journal-title":"Endocrine"},{"key":"R19-20240828","doi-asserted-by":"crossref","first-page":"32714","DOI":"10.1038\/srep32714","article-title":"The efficacy and safety of liraglutide added to metformin in patients with diabetes: A meta-analysis of randomized controlled trials","volume":"6","author":"Gu","year":"2016","journal-title":"Sci Rep"},{"key":"R20-20240828","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3390\/jcm12010145","article-title":"Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: A multidisciplinary expert consensus","volume":"12","author":"Gorgojo-Mart\u00ednez","year":"2022","journal-title":"J Clin Med"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_162_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:48:34Z","timestamp":1787762914000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_162_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_162_23","relation":{},"ISSN":["2230-8210","2230-9500"],"issn-type":[{"value":"2230-8210","type":"print"},{"value":"2230-9500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"2023-04-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-16","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}